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Abstract. 
 
Transforming growth factor-
 
b
 
1 (TGF
 
b
 
1), a 
major promoter of myofibroblast differentiation, in-
duces 
 
a
 
-smooth muscle (sn) actin, modulates the expres-
sion of adhesive receptors, and enhances the synthesis of 
extracellular matrix (ECM) molecules including ED-A 
fibronectin (FN), an isoform de novo expressed during 
wound healing and fibrotic changes. We report here 
that ED-A FN deposition precedes 
 
a
 
-SM actin expres-
sion by fibroblasts during granulation tissue evolution 
in vivo and after TGF
 
b
 
1 stimulation in vitro. Moreover, 
there is a correlation between in vitro expression of 
 
a
 
-SM actin and ED-A FN in different fibroblastic popula-
tions. Seeding fibroblasts on ED-A FN does not elicit 
per se 
 
a
 
-SM actin expression; however, incubation of fi-
broblasts with the anti-ED-A monoclonal antibody 
IST-9 specifically blocks the TGF
 
b
 
1-triggered enhance-
ment of 
 
a
 
-SM actin and collagen type I, but not that of 
plasminogen activator inhibitor-1 mRNA. Interest-
ingly, the same inhibiting action is exerted by the solu-
ble recombinant domain ED-A, but neither of these in-
hibitory agents alter FN matrix assembly. Our findings 
indicate that ED-A–containing polymerized FN is nec-
essary for the induction of the myofibroblastic pheno-
type by TGF
 
b
 
1 and identify a hitherto unknown mecha-
nism of cytokine-determined gene stimulation based on 
the generation of an ECM-derived permissive outside in 
signaling, under the control of the cytokine itself.
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A
 
cquisition 
 
of smooth muscle (SM)
 
1
 
 cell features by
fibroblastic cells is observed during morphoge-
netic processes, wound healing, organ fibrosis, and
stroma reaction to epithelial cancer (for review see Grin-
nell, 1994; Desmoulière and Gabbiani, 1996). 
 
a
 
-SM actin–
expressing myofibroblasts have long been recognized as
suppliers of the driving force for granulation tissue con-
traction (Gabbiani et al., 1972), a mandatory function for
an efficient and rapid wound closure. Moreover, these
cells are involved in the pathogenesis of several fibrotic
diseases, being responsible for tissue retraction and over-
production of extracellular matrix (ECM) components,
such as collagen type I (Zhang et al., 1994). During devel-
opment and under normal conditions, myofibroblasts are
accountable for the generation of the structural and func-
tional complexity of fundamental physiological units such
as the glomerulus (Soriano, 1994) and the lung alveolar
sack (Boström et al., 1996). In addition, myofibroblasts are
typical components of the stroma reaction to epithelial tu-
mors where they secrete proteolytic enzymes and growth
factors which may activate cancer cell invasive behavior
(for review see Rønnov-Jessen et al., 1996). The role of fac-
tors regulating the generation of the myofibroblastic phe-
notype remains largely unknown. Transforming growth
factor-
 
b
 
1 (TGF
 
b
 
1) is the prototype of a large family of
cytokines that control cell proliferation, differentiation,
motility, and apoptosis, exerting their functions both dur-
ing embryogenesis, in terms of pattern formation and tis-
sue specification, and in the adult organism, where they
orchestrate complex phenomena such as inflammation, tis-
sue repair, and neoplastic transformation (Roberts and
Sporn, 1993; Kingsley, 1994; Massagué et al., 1997). It is
well accepted that TGF
 
b
 
1, which is known to stimulate
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1. 
 
Abbreviations used in this paper
 
: ECM, extracellular matrix; FN, fi-
bronectin; MEM, Eagle’s minimum essential medium; PAI-1, plasmino-
gen activator inhibitor-1; rED-A, recombinant ED-A; SM, smooth mus-
cle; TGF
 
b
 
, transforming growth factor 
 
b
 
.
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a
 
-SM actin synthesis by fibroblasts (Desmoulière et al.,
1993; Rønnov-Jessen and Petersen, 1993), upregulates
fibrillar collagen and fibronectin (FN) expression (Ignotz
and Massagué, 1986; Roberts et al., 1986).
FN, a 440-kD dimeric glycoprotein widely distributed in
plasma and in ECM, is expressed at high levels in healing
wounds (Kurkinen et al., 1980). Each FN subunit is
formed by a series of repeating homologous modules and
contains binding sites for cell surface receptors and for
other ECM components. FN polymorphism is due to alter-
native splicing of the type III segments ED-A, ED-B, and
IIICS. Recently, a novel splicing variant lacking the IIICS
region and the segments I-10 and III-15 has been charac-
terized (MacLeod et al., 1996). Two of these alternative
spliced segments, namely ED-A and ED-B, are included
in the so-called cellular FN (Hynes, 1990; Kosmehl et al.,
1996; MacLeod et al., 1996). Previous in situ hybridization
studies have demonstrated that granulation tissue fibro-
blasts show a FN splicing pattern consisting of ED-A and
ED-B domains, similar to that found in the embryo
(ffrench-Constant et al., 1989). In vitro, TGF
 
b
 
1 increases
total FN levels by preferentially promoting accumulation
of the ED-A FN isoform (Balza et al., 1988; Borsi et al.,
1990; Kocher et al., 1990). For this reason we hypothesized
that ED-A FN, interacting with a not yet characterized cell
surface receptor, could transduce signals initiated by
TGF
 
b
 
1 and/or synergize with them, behaving as a crucial
intermediary for the induction of myofibroblastic features,
such as 
 
a
 
-SM actin and collagen type I expression. More-
over, it has been previously suggested that ED-A FN mod-
ulates hepatic stellate cells to 
 
a
 
-SM actin–expressing myo-
fibroblast-like cells (Jarnagin et al., 1994).
It is well known that integrin-mediated adhesion to
ECM regulates transmission of activated growth factor re-
ceptor tyrosine kinases and that convergence of integrin
and growth factor-dependent pathways is required for the
proper stimulation of gene expression, cell growth and dif-
ferentiation (Clarke and Brugge, 1995; Schwartz, 1997;
Schlaepfer and Hunter, 1998). The TGF
 
b
 
 serine/threonine
kinase receptors signal from cell membrane to the nucleus
mainly through the SMAD family of signal transducers
(Heldin et al., 1997). However, it is not yet known whether
and how ECM can influence TGF
 
b
 
 effects on target cells.
Here we provide a molecular dissection of the ECM-gen-
erated pathway that needs to be activated for the induc-
tion of the myofibroblastic phenotype by TGF
 
b
 
.
 
Materials and Methods
 
Antibodies
 
We used an affinity-purified fibronectin polyclonal antibody recognizing
both cellular and plasma FN (Sigma Chemical Co., St. Louis, MO) and
three mouse IgG1 mAbs selectively raised against different domains of
FN isoforms (Borsi et al., 1987; Carnemolla et al., 1987, 1989, 1992): (
 
a
 
)
IST-4, to the fifth FN type III domain shared by cellular and plasma FN;
(
 
b
 
) IST-9, against the ED-A FN type III domain of cellular FN; and (
 
c
 
)
BC-1, recognizing a cryptic epitope within the seventh FN type III do-
main, which is unmasked only when the ED-B domain is included in the
cellular FN molecule. Anti–
 
a
 
SM-1, an IgG2a mAb, against 
 
a
 
-SM actin
(Skalli et al., 1986), and DIA-900, an IgG1 mAb, against the 6
 
3
 
 His tag
(Dianova, Hamburg, Germany), were also used. For control purposes, ir-
relevant antibodies of the same isotypes were used.
 
Purification of FNs and Production of Recombinant 
ED-A Domain
 
Plasma (ED-A 
 
2
 
, ED-B 
 
2
 
) and cellular (ED-A 
 
1
 
, ED-B 
 
1
 
) FNs were
purified from human plasma and from the conditioned medium of the SV-
40–transformed embryonic human lung WI-38-VA cell line as previously
reported (Zardi et al., 1987). The presence or the absence of ED-A and
ED-B in purified FNs was further verified by Western blotting with IST-9
and BC-1 mAbs (Borsi et al., 1987; Carnemolla et al., 1987, 1989).
The 270-bp cDNA sequence coding for the complete amino acid se-
quence of the ED-A domain (Kornblihtt et al., 1984) was generated by
PCR amplification starting from the full-length cellular FN cDNA clone
pFH111 (gift of F.E. Baralle, International Centre for Genetic Engineer-
ing and Biotechnology, Trieste, Italy) and using Pwo 
 
Pyrococcus woesei
 
DNA polymerase (Boehringer Mannheim, Mannheim, Germany) and the
following primers: (
 
a
 
) 5
 
9
 
 CTCGGATCCAACATTGATCGCCCTAAA 3
 
9
 
,
which covers a FN sequence from base 5084 to base 5101 and includes the
underlined BamHI restriction site, and (
 
b
 
) 5
 
9
 
 CTCGGATCCAATAGCT-
GTGGACTGGGT 3
 
9
 
, which covers a FN sequence from base 5342 to base
5359 and includes the underlined BamHI restriction site. PCR product was
isolated, digested with BamHI restriction enzymes, and then cloned in the
pQE-12 expression vector with a 3
 
9 
 
6
 
3 
 
His tag (QIAGEN Inc., Santa
Clarita, CA). 
 
Escherichia coli
 
 were transformed with this construct and
the 6
 
3 
 
His COOH-terminal–tagged recombinant ED-A (rED-A) protein
was purified using a Ni-NTA resin column (QIAGEN Inc.) according to
the manufacturer. 6
 
3 
 
His-tagged rED-A was then dialyzed against PBS
and sterilized through a 0.22-
 
m
 
m filter. After filtration, protein concentra-
tion was established by analyzing absorbance at a 280-nm wavelength.
Protein purity and size were verified by Coomassie blue staining after
SDS-PAGE on a 10% polyacrylamide gel. Immunological protein reactiv-
ity was investigated by Western blotting with mAb IST-9.
 
In Vivo Experimental Procedures
 
Excisional wound granulation tissue was generated as previously de-
scribed (Darby et al., 1990). In brief, on day 0, eight-week-old female
Wistar rats were anaesthetized and a 2 
 
3 
 
2-cm skin wound was made on
the middorsal surface. Granulation tissue samples were collected at 4, 7,
and 12 d after wounding.
All procedures involving animals were reviewed and approved by the
Animal Care Committee at the University of Geneva. These procedures
conform the guidelines as established in the Guide for the Care and Use
of Laboratory Animals and Public Health Service Policy on Human Care
and Use of Laboratory Animals.
 
Double Indirect Immunofluorescence and Confocal 
Laser Scanning Microscopy Analysis
 
Tissue samples were embedded in OCT 4583 (Miles Scientific, Naperville,
IL) and snap frozen in precooled liquid isopentane. 4-
 
m
 
m serial sections
were fixed for 5 min in acetone at 
 
2
 
20
 
8
 
C, air dried for 2 h at room temper-
ature, sequentially incubated with anti–
 
a
 
SM-1, revealed by a TRITC-
tagged goat anti–mouse IgG2a (Jackson ImmunoResearch Labs, Inc.,
West Grove, PA), and then with IST-9, followed by a dichlorotriazinyl
amino fluorescein-labeled goat anti–mouse IgG1 (Jackson ImmunoRe-
search Labs, Inc.).
For the qualitative FN matrix assembly assay, after in vitro blocking ex-
periments with the IST-9 mAb or the rED-A fragment (see below), cul-
tured fibroblastic cells were rinsed in PBS, fixed in 4% paraformaldehyde
for 15 min at room temperature, permeabilized with 0.1% Triton-X 100
for 5 min at room temperature, rinsed in PBS, and then stained in immuno-
fluorescence. The primary monoclonal antibodies used were the affinity-
purified rabbit polyclonal anti-FN antibody (Sigma Chemical Co.) alone
or combined with DIA-900 (Dianova), and then revealed by a TRITC-
tagged goat anti–rabbit and a dichlorotriazinyl amino fluorescein-labeled
goat anti-mouse (both from Jackson ImmunoResearch Labs, Inc.), respec-
tively.
Specimens were observed with a confocal laser scan fluorescence in-
verted microscope (model LSM 410; Carl Zeiss, Oberkochen, Germany)
equipped with two lasers used simultaneously: (
 
a
 
) a helium laser (excita-
tion wavelength at 543 nm) and (
 
b
 
) an argon-neon laser (excitation wave-
length 488 nm). The appropriate combination of filters was used to sepa-
rate excitation and emission spectra. The objective used was an immersion
oil plan-neofluar 63
 
3
 
/1.4. Images of 512 
 
3 
 
512 pixels were stored on an
erasable optical disk (Sony Corp., Tokyo, Japan) and then printed with a 
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Kodak XLS8600 printer (Eastman Kodak Co., Rochester, NY) by means
of dye thermic sublimation technique.
 
Cell Culture and Treatment
 
Passage 5 human fibroblasts obtained from explants of breast skin, palmar
fascia, or Dupuytren’s nodules were plated on Petri dishes containing Ea-
gle’s minimum essential medium (MEM; GIBCO AG, Basel, Switzerland)
supplemented with Monomed (a defined serum-free medium containing
insulin, transferrin, sodium selenite, 2-mercaptoethanol, 2-aminoethanol,
sodium pyruvate, glutamine, and a BSA-oleic acid complex; Common-
wealth Serum Laboratories, Melbourne, Australia), 100 U/ml penicillin,
100 mg/ml streptomycin, and 2 mM 
 
l
 
-glutamine. Cell density was 
 
z
 
1.5 
 
3
 
10
 
4
 
 cells/cm
 
2
 
. They were maintained at 37
 
8
 
C in a humid atmosphere of 5%
CO
 
2
 
 and 95% air. Medium was removed 24 h after plating and fibroblasts
were incubated for 1–6 d in MEM plus Monomed alone or containing 10
ng/ml of TGF
 
b
 
1 (gift of A. Roberts, National Institutes of Health,
Bethesda, MD, and purchased from Sigma Chemical Co.), or TGF
 
b
 
2 (gift
of A. Cox, Novartis, Basel, Switzerland). Passage 5 rat fibroblasts obtained
from explants of subcutaneous tissue, lung, and dermis were plated on Petri
dishes (1.5 
 
3 
 
10
 
4
 
 cells/cm
 
2
 
) containing MEM (GIBCO AG) supplemented
with Monomed (Commonwealth Serum Laboratories) and were cultured at
37
 
8
 
C in a humid atmosphere of 5% CO
 
2
 
 and 95% air for 4 d.
In blocking experiments with mAbs, 50, 150, or 300 
 
m
 
g of each anti-FN
mAb were diluted in 1 ml of 2% gelatin (Sigma Chemical Co.) and then
coated onto 6-cm Petri dishes; coatings of the same volume of 2% gelatin
alone or containing equal amounts of irrelevant mAbs were used as con-
trols. In blocking experiments with rED-A domain 50, 150, or 300 
 
m
 
g of
this fragment were diluted in 1 ml of 2% gelatin (Sigma Chemical Co.)
and then coated onto 6-cm Petri dishes. Cells were then plated on pre-
coated Petri dishes containing MEM supplemented with Monomed (Com-
monwealth Serum Laboratories). Cell density and culture conditions were
the same as above. Medium was removed 24 h after plating and fibroblasts
were incubated for 24 h (extraction of total RNA) or for 3 d (extraction of
proteins) in MEM plus Monomed alone or containing 10 ng/ml of TGF
 
b
 
1
or TGF
 
b
 
2.
The effects of cell adhesion on plasma and cellular FN were investi-
gated as follows. 6-cm Petri dishes were coated with increasing concentra-
tions of plasma FN or cellular FN (25, 50, and 100 
 
m
 
g/ml in PBS, pH 7.4).
Proteins were allowed to bind overnight at 4
 
8
 
C. In some experiments the
Petri dishes were rinsed and blocked for 2 h at 37
 
8
 
C with 3% heat-dena-
tured BSA (RIA grade; Sigma Chemical Co.) in PBS, pH 7.4. In another
set of experiments, the blocking step was omitted. Passage 5 human fibro-
blasts were resuspended in MEM (GIBCO AG) supplemented with
Monomed (Commonwealth Serum Laboratories), 100 U/ml penicillin, 100
mg/ml streptomycin, and 2 mM 
 
l
 
-glutamine, and then plated (1.5 
 
3 
 
10
 
4
 
cells/cm
 
2
 
) on Petri dishes precoated with plasma FN or cellular FN. They
were maintained at 37
 
8
 
C in a humid atmosphere of 5% CO
 
2
 
 and 95% air
for 1–4 d in MEM plus Monomed. All experiments were repeated at least
five times and results were similar with all tested fibroblasts.
 
Western Blot Analysis
 
Cells were harvested and then extracted, or directly extracted on the dish
with a buffer containing 1% SDS (Bio-Rad Laboratories AG, Glattbrugg,
Switzerland), 1% dithiothreitol (Fluka Chemie AG, Buchs, Switzerland),
1 mM PMSF, 1 mM N
 
a
 
-
 
p
 
-tosyl-
 
l
 
-arginine methyl ester (Sigma Chemical Co.)
in 0.4 M Tris-HCl, pH 6.8, immediately sonicated, boiled for 5 min, and then
centrifuged at 10,000 
 
g
 
 for 20 min (model 5415C; Eppendorf Scientific, Inc.,
Hamburg, Germany). Protein content was determined according to Bradford
(1976). Equal amounts of total proteins (15 
 
m
 
g for actin analysis and 50 
 
m
 
g for
FN analysis) were fractionated by SDS-PAGE in acrylamide gels (5–20%
gradient for actin analysis and 6% for FN analysis) and transferred to nitro-
cellulose filters (0.45 
 
m
 
m; Schleicher & Schuell, Dassel, Germany) as previ-
ously described (Serini and Gabbiani, 1996). Filters were then probed with
mAbs IST-9, BC-1, anti–
 
a
 
SM-1, or the affinity-purified rabbit polyclonal
anti-FN antibody (Sigma Chemical Co.). The secondary antibodies were
either a goat anti–mouse IgG or a goat anti–rabbit IgG both conjugated with
alkaline phosphatase (Promega Corp., Madison, WI). Specific binding was
detected by the Problot Western Blot AP system (Promega Corp.).
 
Northern Blot Analysis
 
Total RNA was isolated from cultured cells by TRI REAGENT (Molecu-
lar Research Center, Inc., Cincinnati, OH), according to the manufac-
turer’s instructions. 25 
 
m
 
g of total RNA per lane were denatured by gly-
oxal/DMSO treatment, separated by electrophoresis on a 1% agarose gel,
and then transferred overnight onto an Electran nylon membrane (BDH,
Poole, UK). RNA was immobilized on membrane by cross-linking in a
Stratalinker UV light box (Stratagene, La Jolla, CA). To verify correct
loading and transfer, filters were stained with 0.04% methylene blue in
0.5 M Na-acetate. Filters were then processed for hybridization with three
different probes: (
 
a
 
) a 120-bp 
 
a
 
-SM actin cDNA derived from the rat
 
a
 
-SM actin 3
 
9
 
-untranslated region and recognizing the human 
 
a
 
-SM actin
mRNA in one band at 1.7 kb (prepared in our laboratory by P. Neuville
and T. Christen), (
 
b
 
) a 1,600-bp rat 
 
a
 
1(I) collagen cDNA recognizing the
human 
 
a
 
1(I) collagen mRNA in two typical bands, one at 5.8 kb and the
other one at 4.7 kb (Genovese et al., 1984), and (
 
c
 
) a 600-bp bovine plas-
minogen activator inhibitor type 1 (PAI-1) cDNA (gift of M.S. Pepper,
Department of Morphology, University of Geneva, Switzerland) recog-
nizing the human PAI-1 mRNA in two typical bands, one at 2.6 kb and the
other one at 3.6 kb (Cicila et al., 1989). Probes were labeled by random
priming using the MEGAPRIME DNA labeling system RPN 1606 (Am-
ersham, Little Chalfont, UK). Prehybridization and hybridization were
performed for 4 and 16 h, respectively, at 55
 
8
 
C in 5
 
3 
 
standard saline cit-
rate, 5
 
3 
 
Denhardt’s solution, 0.01% SDS, and 400 
 
m
 
g/ml denatured
salmon sperm DNA. After hybridization, filters were washed twice for 15
min at 55
 
8
 
C in 5
 
3 
 
standard saline citrate and 0.1% SDS. Northern blots
were then exposed on Kodak film at 
 
2
 
70
 
8
 
C (X-Omat SO-282).
 
Quantitation and Statistical Analysis
 
For quantitation, membranes and films corresponding to each Western
and Northern blot experiment were scanned with an Arcus II scanner
(Agfa, Mortsel, Belgium) and analyzed with the ImageQuant Software
Version 3.3 (Molecular Dynamics, Sunnyvale, CA) obtaining the sum of
the pixel values of band areas, as previously described (Bochaton-Piallat
et al., 1998). Depending on the experiment, densitometric analysis results
were presented as fold increase, percentage of the corresponding control,
or percentage of induction inhibition (see Results) and expressed as arith-
metical mean of all experiments performed 6 SEM. For statistical evalua-
tion, results were analyzed with Student’s t test.
Results
ED-A FN Deposition Precedes a-SM Actin Expression 
during Granulation Tissue Evolution
To assess the potential role of ED-A FN as an in vivo in-
ducer of a-SM actin, first we have investigated both spatial
and temporal relationships between ED-A FN and a-SM
actin expression in a rat excisional model of wound repair.
As previously reported (ffrench-Constant et al., 1989) ED-A
FN was not present in fibroblasts of normal dermis under
our conditions (data not shown). Fibroblastic cells con-
taining cytoplasmic actin but not a-SM actin (Fig. 1, a and
b) were abundant within the 4-d-old granulation tissue. At
this time, ED-A FN was already expressed in huge
amounts around them (Fig. 1 b). Only after this early ED-A
FN deposition did a-SM actin start accumulating, evident
around the seventh day (Fig. 1 c), and reached a maximal
peak at the twelfth day (Fig. 1 d). Hence, during wound re-
pair ED-A FN appearance precedes a-SM actin expres-
sion by fibroblastic cells.
Levels of ED-A FN and a-SM Actin Expression
Are Related in Different Fibroblastic Populations;
ED-A Precedes a-SM Actin Induction by TGFb1
Although cultured fibroblastic cells from different origins
display a roughly uniform morphology, they are heteroge-
neous in terms of growth, gene expression, and cell behav-
ior (for review see Sappino et al., 1990). Indeed, when
grown in vitro, fibroblasts from diverse organs can expressThe Journal of Cell Biology, Volume 142, 1998 876
different levels of a-SM actin (Desmoulière et al., 1992;
Xu et al., 1997; Dugina et al., 1998). Therefore, we com-
pared the expression of ED-A FN with that of a-SM actin
in rat fibroblasts cultured from different tissues. Densito-
metric scanning of Western blots showed that a-SM actin
content was similar in subcutaneous and dermal fibro-
blasts (Fig. 2) and was 11.3-fold higher in lung fibroblasts.
Quantitative changes of ED-A FN expressed by fibroblas-
tic populations from different organs mirrored a-SM actin
expression pattern (Fig. 2), being similar in subcutaneous
and dermal fibroblasts and 6.9-fold higher in lung fibro-
blasts. Thus, the ability to synthesize different amounts of
ED-A FN by fibroblastic populations isolated from vari-
ous tissues is proportional to their degree of myofibroblas-
tic differentiation.
We have previously shown (Desmoulière et al., 1993)
that one-week stimulation with TGFb1 (10 ng/ml) induces
a two- to threefold increase of a-SM actin expression in cul-
tured fibroblasts. By a more precise time course analysis
(Fig. 3), we revealed a 2.3-fold increase in a-SM actin only
after 72 h of TGFb1 treatment and a plateau (2.6-fold) at
the fourth day. Similar profiles were obtained in time-
dependent increase of a-SM actin transcript (data not
shown). These data suggest that a-SM actin upregulation
by TGFb1 could be the result of an indirect or synergizing
effect, mediated by one or more intermediary molecules
induced by TGFb1 itself, such as ED-A FN. Indeed, con-
tinue fibroblast stimulation with TGFb1 caused a fivefold
ED-A FN increase within the first 24 h and a further in-
crease (6.5-fold) after 48–72 h (Fig. 3). Therefore, during
TGFb1 treatment of cultured fibroblastic cells, the rise of
ED-A FN precedes and then parallels a-SM actin in-
crease. All together, these data are compatible with a role
for ED-A FN as intermediary between a-SM actin and its
positive regulator TGFb1.
TGFb1 Induction of Myofibroblastic
Phenotype Requires a Permissive ED-A FN–derived
Outside In Signaling
To directly investigate the role of ED-A FN as intermedi-
ary between a-SM actin and TGFb1, we stimulated with
TGFb1 fibroblastic cells plated on gelatin containing spe-
cific blocking mAbs raised against different type III do-
mains of FN (Borsi et al., 1987; Carnemolla et al., 1989,
1992). When examined after 72 h of TGFb1 treatment
(densitometric analysis values being expressed as percent-
ages of the corresponding control), fibroblasts seeded on
gelatin showed the expected a-SM actin increase (217 6
32%) compared with control cells. Plating fibroblasts on
gelatin containing IST-9, an IgG1 against the ED-A do-
main of cellular FN, led to a complete inhibition of a-SM
actin induction (77 6 13%, P , 0.001), whereas neither
BC-1 (an IgG1 against the ED-B containing FN isoform),
nor IST-4 (an IgG1 against the fifth type III domain of
both cellular and plasma FN) were active in this regard
(220 6 29% and 221 6 26%, respectively; Fig. 4). Similar
results were obtained by stimulating cells with TGFb2
(data not shown), which is as effective as TGFb1 in upreg-
ulating a-SM actin both in vivo and in vitro (Serini and
Gabbiani, 1996). The action of IST-9 was dose dependent
(50–300 mg/ml; Fig. 5). Densitometric analysis revealed
that the percentage of inhibition of a-SM actin induction
by TGFb1 was 25 6 5% for 50 mg/ml, 59 6 8% for 150 mg/ml,
and 96 6 15% for 300 mg/ml. It is known that TGFb se-
creted and proteolytically activated by cultured fibroblasts
induces a limited myofibroblastic differentiation (Masur
Figure 1. a-SM actin and ED-A FN expression in granulation tis-
sues at different times after wounding examined by confocal laser
scanning microscopy. Sections of 4- (a and b), 7- (c), and 12-d-old
(d) granulation tissue were double stained for total actin (a, red)
or a-SM actin (b–d, red) and ED-A FN (a–d, green). (a) Fibro-
blastic cells showing an important cytoplasmic staining for total
actin are already present and interact with ED-A FN (yellow
staining, corresponding to the overlay of red and green staining)
which appears de novo in huge amounts as early as 4 d after
wounding within granulation tissue stroma. (b) At 4 d a-SM actin
is localized only in connection with SM-cells of small blood ves-
sels, but not in connection with fibroblasts. (c) A 7-d-old wound
tissue shows focal a-SM actin staining of fibroblasts within an
ED-A FN-rich extracellular network. (d) 12-d-old granulation
tissue fibroblastic cells show wide positivity for a-SM actin. a-SM
actin and ED-A FN are colocalized (c and d; yellow); areas of
colocalization are more abundant in 12- (d) than in 7-d-old (c)
granulation tissue. Bar, 50 mM.
Figure 2. ED-A FN and a-SM
actin expression in cultured
rat fibroblasts isolated from
different tissues. Passage 5
rat fibroblast obtained from
subcutaneous tissue, lung,
and dermis were cultured for
4 d in absence of serum, then
ED-A FN or a-SM actin ex-
pression were evaluated by
Western blot analysis on
equal amounts of total pro-
tein extracts. The levels of
ED-A FN expression paral-
lel those of a-SM actin.Serini et al. ED-A Fibronectin and TGFb1 877
et al., 1996); seeding cells on gelatin containing only IST-9
resulted in a slight lowering of the basal a-SM actin ex-
pression levels (data not shown). As previously described
TGFb1 is able to induce the insertion within FN not only
of the ED-A, but also of the ED-B domain (Balza et al.,
1988). Indeed, Western blot analysis revealed that treat-
ment of fibroblasts with TGFb1 induced an increase of
both ED-A (3.5 6 0.3-fold) and ED-B (7.3 6 0.5-fold) FN
isoforms (Fig. 6). This, together with our blocking experi-
ment data, further confirms the role played by ED-A FN
during myofibroblast formation.
We then tested whether TGFb-regulated genes other
than a-SM actin are dependent on the ED-A FN–driven
signaling. First, we selected collagen type I because its pro-
duction represents a hallmark of myofibroblastic transi-
tion and a key pathogenetic event in the progression of fi-
brotic diseases (Border and Noble, 1994; Zhang et al.,
1994). Northern blot analysis revealed that as expected,
IST-9 treatment inhibited the TGFb1-induced increase of
a-SM actin at the mRNA level by 68 6 12% (P , 0.001;
Fig. 7); moreover, IST-9 mAb inhibited by 95 6 17% the
TGFb1 stimulation of collagen type I mRNA (P , 0.001;
Fig. 7). Hence, collagen type I mRNA induction by TGFb
requires a functionally active ED-A domain within the cel-
lular FN molecule, similar to a-SM actin. The next gene
analyzed was the PAI-1 which plays a crucial role both in
the regulation of extracellular matrix-degrading enzymes
and in the production of active TGFb1 (Lund et al., 1987;
Keski-Oja et al., 1988). Blocking the ED-A domain with
IST-9 mAb did not counteract significantly the increase of
PAI-1 mRNA level induced by TGFb1 (Fig. 7). Thus,
TGFb1 regulation of PAI-1 expression differs from that of
the two main myofibroblastic markers, a-SM actin and
collagen type I.
To investigate whether ED-A FN is not only necessary
for TGFb1 activity on fibroblasts, but also sufficient to
cause their modulation to a-SM actin expressing myofi-
broblasts, cells were plated on Petri dishes precoated with
increasing amounts of ED-A–negative plasma FN or
ED-A–containing cellular FN (refer to Materials and Meth-
ods). 1–4 d after plating, no changes in a-SM actin expres-
sion were noted at any dose used (data not shown). Hence,
ED-A FN does not directly stimulate the conversion of
cultured fibroblasts to myofibroblasts. Next, we studied
the influence of soluble ED-A FN on fibroblast modula-
tion into a-SM actin–expressing myofibroblasts. For this
purpose we used the isolated human rED-A domain (refer
to Materials and Methods). Cells were plated on gelatin
containing carrier solution or rED-A domain and stimu-
lated with TGFb1. After 72 h of TGFb1 treatment, fi-
broblasts seeded on gelatin-containing carrier solution
showed the usual upregulation in a-SM actin expression
compared with control cells (Fig. 8). Plating fibroblasts on
Figure 3. Time course analysis of a-SM actin and ED-A FN ex-
pression modulation by TGFb1 in cultured human subcutaneous
fibroblasts. Fibroblasts were incubated with 10 ng/ml of TGFb1
and total proteins were extracted after different time of continu-
ous stimulation. Immunoblotting after SDS-PAGE shows that
TGFb1 induces a clear-cut a-SM actin increase only after 72 h of
treatment, whereas ED-A FN response to TGFb1 precedes and
then parallels a-SM actin increase. Tracks were loaded with
equal amounts of total proteins. These data are the means of five
independent experiments; the SEMs, which are not represented
in the figure, were always lower than 5% of the values.
Figure 4. ED-A FN antibodies
block TGFb1 induction of a-SM ac-
tin in cultured human subcutaneous
fibroblasts. Cells were seeded on
simple gelatin or on gelatin contain-
ing blocking monoclonal antibod-
ies against different FN type III
domains and then stimulated with
TGFb1 (10 ng/ml) for 3 d; a-SM
actin was then analyzed by Western
blotting on equal amounts of total
proteins. Note that inhibition of
a-SM actin induction by TGFb1 was obtained only when fibro-
blasts were plated on gelatin containing 300 mg/ml of IST-9.
Figure 5. The inhibition of
TGFb1 induction of a-SM ac-
tin by IST-9 is dose depen-
dent. Cells were seeded on
simple gelatin or on gelatin
containing different amounts
(50, 150, and 300 mg/ml) of
IST-9 and then stimulated
with TGFb1 (10 ng/ml) for 3 d;
a-SM actin was then analyzed
by Western blotting on equal
amounts of total proteins.The Journal of Cell Biology, Volume 142, 1998 878
gelatin-containing rED-A domain resulted in a slight de-
crease (15 6 3%, P , 0.001) of a-SM actin basal expres-
sion levels and in a clear-cut inhibition (61 6 5%, P ,
0.001) of a-SM actin induction by TGFb1 (Fig. 8). The ef-
fects exerted by the rED-A domain mimicked the results
obtained using the mAb IST-9 (data not shown; refer to
Fig. 4), suggesting that these two approaches affect the
same biological mechanism. These results can be inter-
preted in different ways. One is that the exogenous ED-A
domain interferes with cellular FN matrix assembly. In-
deed, FN matrix assembly can be disrupted using FN frag-
ments containing critical domains (e.g., III-1 domain or
a5b1-binding domain) or antibodies against these do-
mains (McDonald, 1994). Moreover, TGFb1 is known to
increase the assembly of FN by human fibroblasts (Allen-
Hoffmann et al., 1988). To test this hypothesis, we moni-
tored TGFb1-induced FN matrix assembly by cultured
fibroblasts in the presence of IST-9 mAb or rED-A frag-
ment (as described above) by means of double immuno-
fluorescence staining, using the polyclonal FN antibody,
IST-9 mAb, or the antibody against the 63 His tag of
rED-A. As expected, TGFb1 increased the expression and
assembly of cellular FN when compared with control (Fig.
9, a and b); however, neither IST-9 mAb (Fig. 9 c) nor
rED-A (data not shown) blocked basal and TGFb1-stimu-
lated FN matrix expression and assembly (Fig. 9, a and b).
Interestingly, whereas IST-9 mAb colocalized with FN
fibrils within the assembled matrix, rED-A did not, as re-
vealed by a monoclonal directed against its 63 His tag
(data not shown). These results indicate that the inhibition
of the TGFb1 induction of the myofibroblastic phenotype
by IST-9 mAb and rED-A domain is not due to an inhibi-
tion or a perturbation of FN matrix assembly. Our data are
compatible with the possibility that IST-9 mAb acts by
preventing the ED-A domain to interact with a hypotheti-
cal receptor. Soluble rED-A domain would compete for
the binding of the same receptor. In any event, our results
suggest that in order to be permissive for the action of
TGFb1, the ED-A domain should be incorporated within
the assembled and polymerized FN molecule.
Discussion
TGFb1 is presently considered as the main inducer of the
myofibroblastic phenotype, being able to upregulate a-SM
actin as well as collagen expression in fibroblasts both in
vitro and in vivo (Border and Ruoslahti, 1992; Sporn and
Roberts, 1992; Desmoulière et al., 1993; Rønnov-Jessen
and Petersen, 1993; Zhang et al., 1994). Many data point to
TGFb as a key cytokine in controlling tissue repair, and
disregulation of its production may be a cause of tissue fi-
brosis (Border and Ruoslahti, 1992; Sporn and Roberts,
1992; Border and Noble, 1994). When compared with
other cytokines, a distinctive feature of TGFb is the ability
to control cell adhesion and migration by modulating the
adhesion molecule repertoire (Zambruno et al., 1995) as
well as the synthesis of ECM components such as FN and
collagen (Ignotz and Massagué, 1986; Roberts et al., 1986).
Furthermore, expression of TGFb1 gene has been shown
to be influenced by ECM molecules (Streuli et al., 1986),
suggesting a feedback loop in vivo. However, the mecha-
nisms by which ECM influences TGFb effects on target
cells are not yet fully characterized.
We demonstrate here that ED-A FN deposition pre-
cedes a-SM actin expression both in vivo, during granula-
tion tissue evolution, and in vitro, during TGFb1 fibro-
blast stimulation. Moreover, the degree of myofibroblastic
differentiation exhibited by fibroblasts cultured from dif-
ferent organs is proportional to the different amounts of
ED-A FN they produce. Furthermore, selectively blocking
the ED-A domain of cellular FN by IST-9 mAb inhibits
a-SM actin and collagen type I mRNA induction by TGFb1
in cultured fibroblasts. In contrast, TGFb1 upregulation of
PAI-1 is not influenced by ED-A FN, indicating that the
PAI-1 gene is regulated differently than a-SM actin and
collagen type I. Interestingly, it has been shown that the
increase of collagen type I and actin mRNA induced by
TGFb1 is dependent on protein synthesis, whereas the
induction of PAI-1 transcript is not (Lund et al., 1987;
Keski-Oja et al., 1988; Penttinen et al., 1988). Hence, the
Figure 6. TGFb1 induces the
insertion of both ED-A and
ED-B domain within cellu-
lar FN. Passage 5 human sub-
cutaneous fibroblasts were
stimulated with TGFb1 (10
ng/ml) for 3 d; total FN, ED-A
FN, and ED-B FN were then
evaluated by Western blot analysis on equal amounts of total
proteins. Treatment with TGFb1 determined an increase of total
FN and of both ED-A and ED-B FN isoforms when compared
with control cells.
Figure 7. ED-A FN antibod-
ies block TGFb1 induction of
a-SM actin and collagen type
I, but not of PAI-1 mRNA in
cultured human subcutaneous
fibroblasts. Under the same
experimental conditions de-
scribed in Fig. 4, cells treated
with TGFb1 for 24 h contain
higher levels of a-SM actin,
collagen type I, and PAI-1
mRNA when compared with
untreated cells; treatment with
IST-9 mAb dramatically in-
hibits  a-SM actin and collagen
type I induction, but not that
of PAI-1.
Figure 8. Addition of rED-A do-
main blocks TGFb1 induction of
a-SM actin in cultured human sub-
cutaneous fibroblasts. Cells were
seeded on simple gelatin or on gela-
tin containing 300 mg/ml of rED-A
domain and then stimulated or not
with TGFb1 (10 ng/ml) for 3 d;
a-SM actin was then analyzed by Western blotting on equal
amount of total protein extracts. Treatment of fibroblasts with
rED-A slightly lowered basal a-SM actin expression levels and
inhibited a-SM actin induction by TGFb1.Serini et al. ED-A Fibronectin and TGFb1 879
synthesis of an intermediary protein such as ED-A FN is
necessary for the stimulation by TGFb1 of at least some
morphofunctional genes, i.e., a-SM actin and collagen
type I. Thus, it appears that TGFb1 regulates gene expres-
sion through different mechanisms, possibly according to
the biological functions exerted by the corresponding pro-
teins.
Hautmann and colleagues (1997) have identified a
TGFb response element in the a-SM actin promoter that
drives the stimulation of a-SM actin gene expression in
concert with two CArG elements in rat sn cells. We dem-
onstrate here that, at least in fibroblastic cells, the pres-
ence of functional ED-A FN is mandatory for a-SM actin
induction by TGFb. The ED-A FN signaling is necessary
but not sufficient for a-SM actin–positive regulation by
TGFb. Taken together, these observations suggest that
TGFb activation of a-SM actin expression results from the
cooperation of two signal transduction pathways raised re-
spectively by TGFb and ED-A FN.
The observation that treatment of fibroblasts with the
soluble rED-A domain inhibits TGFb1 induction of the
myofibroblastic phenotype without interfering with FN as-
sembly (similar to treatment with IST-9 mAb) allows to
hypothesize the existence of an hitherto unknown specific
receptor interacting with the ED-A domain. It is worth
noting that a TGFb-dependent morphogenic process, i.e.,
the cellular condensation event that occurs during chon-
drogenesis (Leonard et al., 1991), has been recently shown
to be spatiotemporally correlated to and to depend upon
the ED-A domain insertion in cellular FN; moreover, this
crucial step in skeletal pattern formation was similarly in-
hibited by the soluble rED-A domain and an anti–ED-A
antibody (Gehris et al., 1997). All together, these data sug-
gest that the ED-A–dependent signaling described here is
a general mechanism used by TGFb to finely regulate the
correct execution of different morphogenetic programs.
Cell binding activity of FN was originally localized in the
tenth type III repeat to the amino acid sequence RGD
(Pytela et al., 1987) and in the alternative spliced IIICS re-
gion to the amino acid sequence LDV (Humphries et al.,
1988). The recent demonstrations that activated b1 inte-
grins mediate cell adhesion and spreading on recombinant
FN type III repeats lacking RGD have expanded the
possibility for integrin-dependent cell–ECM interactions
(Chi-Rosso et al., 1997; Moyano et al., 1997). Xia and Culp
(1994) have shown that the isolated rED-A domain pro-
motes cell adhesion, whereas Manabe et al. (1997) have
demonstrated that cells adhere and migrate more actively
on the ED-A FN probably because ED-A induces a con-
formational change of FN, which in turn increases the ac-
cessibility of the RGD motif to integrin a5b1. We hypoth-
esize that the ED-A domain interacting with its receptor
acts in conjunction with the integrin-binding sites of FN to
switch on a qualitatively different and more complex sig-
naling. Moreover, we show here that to exert its permis-
sive function on TGFb activity, the ED-A domain must be
presented within the proper molecular context, that is the
polymerized FN molecule; indeed isolated the rED-A do-
main inhibits this function. Thus, the ED-A receptor is
able to bind its domain independently of the molecular
context, but generates intracellular signals only in a con-
formationally sensitive manner. In this respect, two recent
reports (Shrivastava et al., 1997; Vogel et al., 1997) outline
an intriguing new paradigm for ECM signaling: the recep-
tor tyrosine kinases DDR1 and DDR2 bind to and are ac-
tivated by collagen in a conformation-dependent way. It is
proposed that signals generated by the activation of these
receptors act in concert with signals generated by binding
of ECM molecules to classical integrins. Further work
along these lines may help in identifying the hypothetical
ED-A cell-surface receptor.
Unlike Jarnagin et al. (1994) and Van De Water et al.
(Van De Water, L., C. Reimer, L. Plantefaber, R.O. Hynes,
and J.H. Peters. 1996. Abstract from Wound Repair in
Context, Keystone Symposia, Taos, NM), we were unable
to induce a-SM actin expression by simply plating cells on
ED-A–containing cellular FN. This discrepancy may be
related to the different cell types (hepatic stellate cells ver-
sus fibroblasts) or alternatively to the different sources of
FN the authors used in their assay system, e.g., endothelial
cell-derived ECM and commercial FNs. Indeed, an in-
creasing number of cytokines, including TGFb, have been
found associated with the ECM proteins and both latent
and active form of TGFb have been found to bind cellular
FN of many cell types, endothelial cells included (Taipale
and Keski-Oja, 1997). Moreover, many commercial sources
of FN contain TGFb activity (Fava et al., 1987). Our data
show that ED-A FN is necessary, but not sufficient, to in-
duce myofibroblastic differentiation and that it exerts a
permissive effect on TGFb activity.
It is well accepted that ED-A FN is synthesized by mes-
enchymal cells which are driven toward an a-SM actin–
positive phenotype by TGFb in many physiological and
pathological settings, such as wound healing (Gabbiani et al.,
Figure 9. FN matrix assem-
bly evaluation on TGFb1
stimulated fibroblasts after
IST-9 mAb treatment. Sub-
cutaneous fibroblasts were
plated on simple gelatin (a
and b) or on gelatin contain-
ing IST-9 mAb (c) and then
stimulated with TGFb1 (10
ng/ml) for 3 d (b and c). Cells
were then stained with an
anti-total FN rabbit poly-
clonal antibody. When compared with control (a), TGFb1 stimulation determines an increase in FN expression and assembly by fibro-
blasts (b). IST-9 mAb treatment (c) does not interfere with TGFb1 action. Bar, 25 mM.The Journal of Cell Biology, Volume 142, 1998 880
1972; Darby et al., 1990), Dupuytren’s disease (Berndt et al.,
1995), organ fibrosis (Schürch et al., 1992), developing
aorta (Glukhova et al., 1990), arterial intimal thickening
(Glukhova et al., 1989), and stroma reaction to epithelial
cancers (Pujuguet et al., 1996). Our results support that in
such different systems ED-A FN acts as a necessary ECM
molecule that allows TGFb to induce SM differentiation.
Pathological deposition within tissues of ECM compo-
nents results in fibrosis, which may alter irreversibly the
function of the involved organ. Recently it has been dem-
onstrated that a-SM actin–expressing myofibroblasts are
the main collagen type I synthesizing cells during fibrosis
(Zhang et al., 1994). Blocking TGFb1 with antibodies or
with decorin was therapeutic in many models of fibrotic
disease (Border and Noble, 1994) and, where investigated,
was associated to a significant attenuation of ED-A FN
deposition (Isaka et al., 1996; Giri et al., 1997). However,
extreme reduction of TGFb1 levels or mutation in its re-
ceptors could be unfavorable, causing autoimmune-like
disease (Shull et al., 1992; Kulkarni et al., 1993) and lead-
ing to malignant transformation (Marx, 1995). ED-A FN
could be considered as a potential target for therapy since:
(a) it is an extracellular, easily reachable molecule; and (b)
in contrast to TGFb1, it drops to low levels in adult tissues
(Kornblihtt et al., 1996) decreasing the probability that its
blocking results in side effects. Thus, the outside in signal
described here represents another possible target for phar-
macological studies on myofibroblastic activities during
developmental and pathological events. Notably, recent
studies support the feasibility of in vivo targeting alterna-
tively spliced exons of FN present in pathological tissues
but not in their normal counterparts (Mariani et al.,
1997a,b; Neri et al., 1997).
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